A Phase 1b, Open-label, Dose-finding Study of AMG 706 in Combination With Gemcitabine and Erlotinib to Treat Subjects With Solid Tumors

Phase 1 Completed 57 enrolled Amgen

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study is an open-label, dose-finding study to determine the target or maximum-tolerated dose and to characterize the safety and pharmacokinetic profile of AMG 706 administered in combination with erlotinib with or without gemcitabine in subjects with solid tumors.

Timeline

Start: 2005-09
Primary completion: 2008-04
Completion: 2010-02

Publications

Kotasek D, Tebbutt N, Desai J, Welch S, Siu LL, McCoy S, Sun YN, Johnson J, Adewoye AH, Price T. Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study. BMC Cancer. 2011 Jul 26;11:313. doi: 10.1186/1471-2407-11-313.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	motesanib	Small molecule	50 mg	—
Comparator	motesanib	Small molecule	75 mg	—
Comparator	motesanib	Small molecule	125 mg	—

Indications

No indication recorded.